Press Releases
Moderna Partners with Takeda and the Government of Japan to Supply 50 Million Doses of mRNA Vaccine Against COVID-19 to Japan
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, confirmed that...
Press Releases
Thermo Fisher Scientific Expands Direct-to-Patient Clinical Trials Service Offerings
A newly expanded Direct-to-Patient service offering supports decentralized clinical trials to minimize clinical trial length and costs while maximizing patient enrollment and participation rates....
News
BioInvent licenses anti-Fc?RllB antibody BI-1206 to CASI Pharmaceuticals for Greater China region
BioInvent International AB, a biotechnology company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy, and CASI Pharmaceuticals, Inc, a...
News
Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet...
News
Lilly to Supply 300,000 Vials of Neutralizing Antibody Bamlanivimab in an Effort to Fight COVID-19
Eli Lilly and Company announced an initial agreement with the U.S. government to supply 300,000 vials of bamlanivimab (LY-CoV555) 700 mg, an investigational neutralizing...
News
Integration of Movilitas.Cloud and NiceLabel Simplifies Serialized Label Printing for Highly Regulated Industries
Movilitas today announced the integration of its Movilitas.Cloud with NiceLabel’s cloud-based label printing solution to simplify serialized label printing for highly regulated industries. With...
News
U.S. FDA Approves Gileads Antiviral Veklury (remdesivir) for Treatment of COVID-19
Gilead Sciences, Inc. announced that the U.S. FDA has approved the antiviral drug Veklury® (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read